Abstract

BackgroundThe role of meteorin (METRN) in colorectal cancer has not been reported previously. We aimed to explore the relationship between METRN and colorectal cancer (CRC) prognosis.MethodsData were retrieved from the Gene Expression Omnibus database. Gene expression values were log2 transformed and normalized by quantile normalization. Missing values were imputed with the R impute package. Differentially expressed genes were analyzed using the R limma package. METRN expression was compared between normal and CRC tissues and among different stages and subtypes of CRC. We assessed the relationship between METRN and KRAS/BRAF mutations in CRC. Five‐year overall (OS), disease‐free (DFS), and disease‐specific survival (DSS) rates were determined by Kaplan–Meier analysis and analyzed by log‐rank test.Results METRN was expressed at a higher level in CRC (p = .0011) than in normal tissues, especially in advanced stages (p = .0343). METRN expression levels were higher in the MSI (dMMR) subtype (p < .001) and usually with BRAF mutations (p < .0001). METRN overexpression was associated with poor prognosis and low OS (p = .01014), DFS (p = .0146), and DSS (p < .0001) rates.Conclusion METRN overexpression is a predictive factor for poor prognosis in patients with CRC.

Highlights

  • Colorectal cancer (CRC) is the third most common malignant tumor globally, and more than 1.3 million people are diagnosed with colorectal cancer (CRC) each year (Allemani et al, 2018)

  • We found that METRN played a critical role in CRC and can be used as a prognostic indicator in patients with CRC

  • We found that METRN was expressed at a high level in CRC tissues compared with normal colorectal tissues

Read more

Summary

Introduction

Colorectal cancer (CRC) is the third most common malignant tumor globally, and more than 1.3 million people are diagnosed with CRC each year (Allemani et al, 2018). For advanced CRC, 5-year survival rates have been reported to be less. We aimed to explore the relationship between METRN and colorectal cancer (CRC) prognosis. METRN expression was compared between normal and CRC tissues and among different stages and subtypes of CRC. Five-year overall (OS), disease-free (DFS), and disease-specific survival (DSS) rates were determined by Kaplan–Meier analysis and analyzed by log-rank test. Results: METRN was expressed at a higher level in CRC (p = .0011) than in normal tissues, especially in advanced stages (p = .0343). METRN expression levels were higher in the MSI (dMMR) subtype (p < .001) and usually with BRAF mutations (p < .0001). METRN overexpression was associated with poor prognosis and low OS (p = .01014), DFS (p = .0146), and DSS (p < .0001) rates. Conclusion: METRN overexpression is a predictive factor for poor prognosis in patients with CRC

Objectives
Findings
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.